Health grants for Small business

Expected Outcome: Proposals should demonstrate the following expected outcomes: A sound understanding of the specific needs of industrial users (including but not limited to innovative SMEs, startups and scaleups) for Technology infrastructure services in specific priority areas including but not limited to advanced materials, clean energy, or health and biotechnology; Increased opportunities for industrial users for development, testing, up-scaling and deployment of new technologies via the use of services offered by Technology Infrastructures; Strengthened innovation and technology development capacity of European SMEs, startups and scaleups via improved access to Technology Infrastructures; Attractiveness and effectiveness of the developed access schemes for broadening the range of Technology Infrastructures users, especially for startups and scaleups, including with transnational access. Scope: Startups, scaleups and other innovative SMEs require access to state-of-the-art research and technology facilities, equipment and expertise to test, upscale, validate new products and technologies, shortening the time-to-market and increasing the chances for a successful…

The purpose of this Notice of Funding Opportunity (NOFO) is to leverage NICHD clinical research Network infrastructure relevant to infants, children, women, pregnant and lactating women, and persons with disabilities to conduct innovative, multisite, investigator-initiated clinical trials and observational studies. This NOFO will utilize a bi-phasic (UG3/UH3), milestone-driven mechanism consisting of a start-up phase (UG3) and a full enrollment and clinical trial implementation phase (UH3). Applications submitted in response to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases. A UG3 project (phase I) that meets its milestones will be administratively considered by NICHD and prioritized for transition to the UH3 award (phase II). This NOFO provides an opportunity to leverage NICHD clinical research Network infrastructure as a platform for investigator-initiated innovative hypotheses by any investigator in the extramural community. Applications must be submitted as investigator-initiated, multi-Project Director/Principal Investigator (PD/PI) grant applications in conjunction with the respective NICHD-supported Network Data Coordinating Center (DCC), or equivalent as determined by the NICHD.

This Notice of Funding Opportunity (NOFO) announces the renewal of the NIH Research Evaluation and Commercialization Hub (REACH) program, established to facilitate and accelerate the translation of academic biomedical discoveries into products that improve patient care and public health. Through this program, NIH will provide the qualifying institutions with the funds to seed the creation of academic entrepreneurship Hubs. Hubs will be responsible for providing innovators with both the initial investment and resources to support the proof-of-concept work and the mentorship in product development and commercialization needed to develop high priority technologies within the NIH's mission. Funded Hubs are intended to work as a consortium to enable: (1) the infrastructure for identifying the most promising technologies, (2) funding for product definition studies (e.g. feasibility studies, prototype development, proof-of-concept studies) provided to individual researchers, (3) access to resources and expertise in areas required for early stage technology development (including scientific, regulatory, reimbursement, business, legal, and project management), and (4) skills development and hands-on experience in entrepreneurship. Establishing public-private partnerships and providing additional non-federal funds will be critical for success. This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite applications from eligible organizations to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.

The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.

Expected Impact: FOR ALL THREE THEMATIC PRIORITIES: Expected impact at the closure of the project (non-exhaustive list): Creation of new value chains in less developed regions and transition regions; Application and deployment of innovative technologies and solutions (new to the region) in less developed and transition regions (innovation diffusion); Exploitation of project results; Innovative technologies tested and adopted by the market; Innovative solutions deployed improving businesses confidence, competences and means to digitalise and grow; Contribution to digitisation and health systems transformation, through various types of innovation and the supply of IT services; Uptake of technologically/economically reliable and viable solutions on the market; Deployment of new technologies fostering the growth of Europe’s manufacturing sector; Innovative technologies adopted by SMEs; Identification of possible sources of funding/funding mix, to cover the residual investment needs (public-private partnerships for the deployment of innovation, the collaboration with venture capitals, EIB group loans etc); Strengthening innovation diffusion channels; Reinforcing the capacity of regions…

Expected Impact: FOR ALL THREE THEMATIC PRIORITIES: Expected impact at the closure of the project (non-exhaustive list): Innovative technologies tested and adopted by the market; Innovative solutions deployed improving businesses confidence, competences and means to digitalise and grow; Contribution to digitisation and health systems transformation, through various types of innovation and the supply of IT services; Uptake of technologically/economically reliable and viable solutions on the market; Deployment of new technologies fostering the growth of Europe’s manufacturing sector; Innovative technologies adopted by SMEs; Identification of possible sources of funding/funding mix, to cover the residual investment needs (public-private partnerships for the deployment of innovation, the collaboration with venture capitals, EIB group loans etc); Strengthening innovation diffusion channels; Reinforcing the capacity of regions to co-invest together, joining forces on common S3 investment priorities (interregional investments). Long-term impact (non-exhaustive list): Increased companies’ productivity and efficiency; Improved user-friendly, accessible and interoperable public…

The Small Business Technology Transfer (STTR) grant program helps United States small business concerns (SBCs) that partner with a nonprofit research institution bring scientific innovations to the marketplace. The STTR program supports feasibility studies to later stage research and development (R&D) needed to develop a commercial product.

The Small Business Innovation Research (SBIR) program helps United States small business concerns (SBCs) bring scientific innovations to the marketplace. The SBIR program supports feasibility studies to later research and development (R&D) needed to develop a commercial product.

The NIH Phase IIB Strategic Breakthrough award bridges the funding gap between the end of a Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase II award and commercialization. The Phase IIB Strategic Breakthrough provides previously funded NIH SBIR or STTR projects additional support for later-stage research and development (R&D).

The Institutional Development Awards (IDeA) program supports biomedical research capacity building in states that have historically received low levels of NIH funding. The Centers of Biomedical Research Excellence: Development Phase (COBRE-D) program supports institutions in IDeA states to increase their biomedical research capacity in a broad scientific area of strategic importance to them but for which they have limited existing infrastructure or expertise.COBRE-D supports a long-term institutional vision focused on the recruitment and mentoring of early-career investigators with supplemental start-up packages for new hires, the establishment of research facilities, and enhancement of research administration support services. This program serves as an on-ramp for less-resourced institutions to the Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) program. This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.

The Commercialization Readiness Pilot (CRP) program helps small business concerns (SBCs) move NIH-funded SBIR or STTR projects from late-stage development to commercialization. The CRP supports later-stage research and development (R&D) and/or technical assistance that Phase II and Phase IIB Strategic Breakthrough awards do not typically support. This includes:Independent replication or confirmation of key studiesIND- or IDE-enabling studiesClinical studiesManufacturing scale-up and related quality activitiesRegulatory and other specialized technical supportSBCs may subcontract (outsource) a significant amount of the work in a CRP to meet the project goals.